欧洲肥厚性和瘢痕疙瘩治疗市场预测至 2027 年 - 按疤痕类型(肥厚性和瘢痕疙瘩)、产品类型(激光产品、局部产品、注射剂、其他产品)和最终用户(医院、诊所、和家庭护理)

Historic Data: 2018-2019   |   Base Year: 2020   |   Forecast Period: 2021-2027


No. of Pages: 101    |    Report Code: TIPRE00025197    |    Category: Life Sciences

Europe Hypertrophic and Keloid Scar Treatment Market

市场介绍

欧洲增生性疤痕疙瘩治疗市场分为德国、英国、法国、意大利、西班牙、欧洲其他地区。由于对肥厚性和疤痕疙瘩治疗的研究和开发的不断增长、疤痕疙瘩和损伤发生率的增加、治疗肥厚性和疤痕疙瘩的激光疗法的新技术以及有利于疤痕治疗的美容行业的不断发展,预计该市场的增长。德国是欧洲地区最大的国家之一,拥有发达的医疗保健产业。该国拥有在全球市场运营的知名企业。此外,该国还设有监管机构,为各种健康状况的治疗提供指导方针和法规。同样,对于肥厚性疤痕和疤痕疙瘩的治疗,国家于2012年推出了S2k病理性疤痕治疗指南,最近又进行了更新。此外,德国的医疗保健系统提供最便宜的保险,使人们能够选择各种医疗保健服务。此外,该国因足球造成的运动损伤病例最多。因此,各种球员都会接受疤痕治疗。因此,预计上述因素将推动该国的疤痕治疗并在预测期内撬动市场的增长。

 

在所有欧洲国家中,西班牙、意大利、由于冠状病毒病例和死亡人数不断增加,德国、法国和英国受到的影响最为严重。根据世界统计,西班牙、意大利、德国、法国和英国的病例数分别为225万、237万、200万、9500万、336万。这些国家的死亡人数也很高。据新闻报道,在意大利,由于 Covid-19 紧急情况,数千名需要化疗、扫描、移植和手术的癌症患者变得困难。国家和国际组织发布了几项指南,试图帮助应对疑似或确诊的 COVID-19 患者。此外,由于担心新冠病毒突变可能导致病例再次增加,德国将包括关闭学校和商店在内的大流行禁令延长至2月中旬。除了将餐馆、商店和学校的关闭期限延长至2月14日外,默克尔和德国16个州的州长还决定让公民在公共交通和超市佩戴功能更强大的FFP2或KN95口罩。现在,雇主将被命令鼓励工人尽可能在家工作,以防止办公室感染。与一般人群相比,肥厚性疤痕和疤痕疙瘩治疗患者被认为对 COVID-19 的敏感性较低。欧洲长期以来一直是皮肤科手术领域动态发展的地区,适应不同的文化、传统以及外科和医学理念。最近,这些变化更加显着和迅速。

市场概况和动态

欧洲肥厚性疤痕和疤痕疙瘩治疗市场预计将从2020年的13.7688亿美元增长到2027年的27.0559亿美元;预计2020年至2027年复合年增长率为10.1%。 开拓新兴国家市场;欧洲新兴国家报告的烧伤病例数量最多。然而,这些国家的肥厚性疤痕和疤痕疙瘩治疗存在一些差异。治疗程序主要基于对这些纤维化皮肤病的病理机制的了解。种族造成的差异给医生制定治疗方案带来了挑战。此外,不确定的诊断和不明确的治疗指南也可能导致为具有不同病理基因组成的人提供治疗的差异。因此,治疗程序的差异可能为肥厚性疤痕和疤痕疙瘩治疗市场参与者扩大业务提供重要的增长机会。这促进了肥厚性疤痕和疤痕疙瘩治疗市场的增长。

关键细分市场

<根据疤痕类型,肥厚性疤痕疙瘩治疗市场分为肥厚性疤痕疙瘩和疤痕疙瘩。 2019年,肥厚性疤痕领域占据最大的市场份额。根据产品类型,肥厚性疤痕疙瘩治疗市场分为激光产品、局部产品、注射剂和其他产品。 2019年,注射剂领域占据了最大的市场份额。根据最终用户,肥厚性和疤痕疙瘩治疗市场分为医院、诊所和家庭护理。 2019 年,医院细分市场占据最大市场份额。

主要来源和上市公司

一些主要的主要来源准备这份关于欧洲肥厚性疤痕和疤痕疙瘩治疗市场的报告时参考的二手来源包括公司网站、年度报告、财务报告、国家政府文件和统计数据库等。报告中列出的主要公司有 Alliance Pharma PLC

Mölnlycke Health Care AB。

Smith & Inc.。 Nephew

Newmedical Technology Inc.

Lumenis

Sonoma Pharmaceuticals, Inc

Suneva Medical

strong>HRA Pharma

Perrigo Company plc

等等

< em>购买报告的理由

  • 了解欧洲肥厚性疤痕和疤痕疙瘩治疗市场格局和确定最有可能保证丰厚回报的细分市场
  • 了解欧洲肥厚性和疤痕疙瘩治疗市场不断变化的竞争格局,保持领先地位
  • 有效规划并购;A 和合作伙伴通过确定最有希望销售的细分市场来涉足欧洲肥厚性和疤痕疙瘩治疗市场
  • 通过对欧洲肥厚性和疤痕疙瘩各个细分市场的市场表现进行敏锐和全面的分析,帮助做出明智的业务决策和疤痕疙瘩治疗市场
  • 获取欧洲地区2020-2027年各细分市场的市场收入预测

欧洲肥厚性和瘢痕疙瘩治疗市场细分

按疤痕类型

  • 肥厚性
  • 疤痕疙瘩

按产品类型

  • 注射剂
  • 外用
    • 凝胶
    • 硅胶片
    • 面霜
    • 其他
  • 激光
    • CO2
    • 脉冲染色
    • 其他
  • 其他

作者

最终用户

  • 医院< /li>
  • 诊所
  • 家庭护理

 < /p>

按国家/地区

  • 德国
  • 英国
  • 法国< /li>
  • 意大利
  • 西班牙
  • 欧洲其他地区

 

< p>

公司简介

  • Alliance Pharma PLC
  • HRA Pharma
  • Mölnlycke Health Care AB。
  • >
  • Newmedical Technology Inc.
  • Perrigo Company plc
  • Lumenis
  • Smith & Co.侄子
  • 索诺玛制药公司
  • Suneva Medical
 

Europe Hypertrophic and Keloid Scar Treatment Strategic Insights

Strategic insights for Europe Hypertrophic and Keloid Scar Treatment involve closely monitoring industry trends, consumer behaviours, and competitor actions to identify opportunities for growth. By leveraging data analytics, businesses can anticipate market shifts and make informed decisions that align with evolving customer needs. Understanding these dynamics helps companies adjust their strategies proactively, enhance customer engagement, and strengthen their competitive edge. Building strong relationships with stakeholders and staying agile in response to changes ensures long-term success in any market.

strategic-framework/europe-hypertrophic-and-keloid-scar-treatment-market-strategic-framework.webp
Get more information on this report

Europe Hypertrophic and Keloid Scar Treatment Report Scope

Report Attribute Details
Market size in 2020 US$ 1,376.88 Million
Market Size by 2027 US$ 2,705.59 Million
Global CAGR (2020 - 2027) 10.1%
Historical Data 2018-2019
Forecast period 2021-2027
Segments Covered By 疤痕类型
  • 增生性
  • 瘢痕疙瘩
By 产品类型
  • 激光产品
  • 外用产品
  • 注射剂
  • 其他产品
By 最终用户
  • 医院
  • 诊所
  • 家庭护理
Regions and Countries Covered 欧洲
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 意大利
  • 欧洲其他地区
Market leaders and key company profiles
  • Alliance Pharma PLC
  • HRA Pharma
  • Mölnlycke Health Care AB.
  • Newmedical Technology Inc.
  • Perrigo Company plc
  • Lumenis
  • Smith & Nephew
  • Sonoma Pharmaceuticals, Inc
  • Suneva Medical
  • Get more information on this report

    Europe Hypertrophic and Keloid Scar Treatment Regional Insights

    The regional scope of Europe Hypertrophic and Keloid Scar Treatment refers to the geographical area in which a business operates and competes. Understanding regional nuances, such as local consumer preferences, economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved regions or adapting their offerings to meet regional demands. A clear regional focus allows for more effective resource allocation, targeted marketing, and better positioning against local competitors, ultimately driving growth in those specific areas.

    geography/europe-hypertrophic-and-keloid-scar-treatment-market-geography.webp
    Get more information on this report

    The List of Companies - Europe Hypertrophic and Keloid Scar Treatment Market

    1. Alliance Pharma PLC
    2. HRA Pharma
    3. Mölnlycke Health Care AB.
    4. Newmedical Technology Inc.
    5. Perrigo Company plc
    6. Lumenis
    7. Smith & Nephew
    8. Sonoma Pharmaceuticals, Inc
    9. Suneva Medical
    Frequently Asked Questions
    How big is the Europe Hypertrophic and Keloid Scar Treatment Market?

    The Europe Hypertrophic and Keloid Scar Treatment Market is valued at US$ 1,376.88 Million in 2020, it is projected to reach US$ 2,705.59 Million by 2027.

    What is the CAGR for Europe Hypertrophic and Keloid Scar Treatment Market by (2020 - 2027)?

    As per our report Europe Hypertrophic and Keloid Scar Treatment Market, the market size is valued at US$ 1,376.88 Million in 2020, projecting it to reach US$ 2,705.59 Million by 2027. This translates to a CAGR of approximately 10.1% during the forecast period.

    What segments are covered in this report?

    The Europe Hypertrophic and Keloid Scar Treatment Market report typically cover these key segments-

  • 疤痕类型 (增生性, 瘢痕疙瘩)
  • 产品类型 (激光产品, 外用产品, 注射剂, 其他产品)
  • 最终用户 (医院, 诊所, 家庭护理)
  • What is the historic period, base year, and forecast period taken for Europe Hypertrophic and Keloid Scar Treatment Market?

    The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Europe Hypertrophic and Keloid Scar Treatment Market report:

  • Historic Period : 2018-2019
  • Base Year : 2020
  • Forecast Period : 2021-2027
  • Who are the major players in Europe Hypertrophic and Keloid Scar Treatment Market?

    The Europe Hypertrophic and Keloid Scar Treatment Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:

  • Alliance Pharma PLC
  • HRA Pharma
  • Mölnlycke Health Care AB.
  • Newmedical Technology Inc.
  • Perrigo Company plc
  • Lumenis
  • Smith & Nephew
  • Sonoma Pharmaceuticals, Inc
  • Suneva Medical
  • Who should buy this report?

    The Europe Hypertrophic and Keloid Scar Treatment Market report is valuable for diverse stakeholders, including:

    • Investors: Provides insights for investment decisions pertaining to market growth, companies, or industry insights. Helps assess market attractiveness and potential returns.
    • Industry Players: Offers competitive intelligence, market sizing, and trend analysis to inform strategic planning, product development, and sales strategies.
    • Suppliers and Manufacturers: Helps understand market demand for components, materials, and services related to concerned industry.
    • Researchers and Consultants: Provides data and analysis for academic research, consulting projects, and market studies.
    • Financial Institutions: Helps assess risks and opportunities associated with financing or investing in the concerned market.

    Essentially, anyone involved in or considering involvement in the Europe Hypertrophic and Keloid Scar Treatment Market value chain can benefit from the information contained in a comprehensive market report.